Delaware (State or other jurisdiction of

incorporation or organization)

UNITED STATES

SECURITI

	Washington, D.C. 20549	
	FORM 8-K	
	Current Report	
	ant to Section 13 or 15(d) of the urities Exchange Act of 1934	
e of Report (D	Pate of earliest event reported): February 4	i, 2004
	ttle Genetics, Inc.	
	0-32405 (Commission File Number)	91-187438 (I.R.S. Emplo
		Identification 1

21823 30th Drive SE

Bothell, Washington 98021

 $(Address\ of\ principal\ executive\ offices,\ including\ zip\ code)$

(425) 527-4000

(Registrant s telephone number, including area code)

Item 5. Other Events and Required FD Disclosure

The Registrant is filing as an exhibit hereto an underwriting agreement to be incorporated by reference into its Registration Statement on Form S-3 (File No. 333-111269), originally filed with the Securities and Exchange Commission on December 17, 2003.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

Exhibit No.	Description
1.1	Underwriting Agreement, dated as of February 4, 2004, by and among Seattle Genetics, Inc. and the underwriters listed on Schedule I thereto.
99.1	Press release of Seattle Genetics, Inc. announcing the pricing of its public offering of 7,000,000 shares of common stock.

Item 9. Regulation FD Disclosure

On February 5, 2004, Seattle Genetics, Inc. issued a press release announcing the pricing of its public offering of 7,000,000 shares of common stock. A copy of the press release is attached hereto as Exhibit 99.1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SEATTLE GENETICS, INC.

(Registrant)

Date: February 5, 2004 By: /s/ Clay B. Siegall

Clay B. Siegall, Ph.D. President and Chief Executive Officer

INDEX TO EXHIBITS

Exhibit No.	Description
1.1	Underwriting Agreement, dated as of February 4, 2004, by and among Seattle Genetics, Inc. and the underwriters listed on Schedule I thereto.
99.1	Press release dated February 5, 2004 of Seattle Genetics, Inc. announcing the pricing of its public offering of 7,000,000 shares of common stock.